Patents Assigned to Fujisawa Pharmaceutical Co., Ltd.
  • Patent number: 6787543
    Abstract: A compound of the formula (I): in which Z, R1, R2, R8, R10, R11, R12, R13 and R14 are each as defined in the description, or a salt thereof. The object compound of the present invention has pharmacological activities such as Tachykinin antagonism, and is useful for manufacture of a medicament for treating or preventing Tachykinin-mediated diseases.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: September 7, 2004
    Assignee: Fujisawa Pharmaceutical Co., Ltd.
    Inventors: Kazuhiko Take, Chiyoshi Kasahara, Shinji Shigenaga, Hidenori Azami, Yoshiteru Eikyu, Kazuo Nakai, Masataka Morita
  • Publication number: 20040162250
    Abstract: Administration of a decoy, i.e. a compound which specifically antagonizes the nucleic acid domain to which NF-&kgr;B is bound, is effective in the treatment and prevention of diseases caused by the transcriptional regulatory factor NF-&kgr;B, such as ischemic diseases, inflammatory diseases, autoimmune diseases, cancer metastasis and invasion, and cachexia.
    Type: Application
    Filed: February 14, 2003
    Publication date: August 19, 2004
    Applicant: Fujisawa Pharmaceutical Co., Ltd.
    Inventors: Ryuichi Morishita, Toshio Ogiwara, Toshiko Sugimoto, Kazuhiro Maeda, Ikuo Kawamura, Toshiyuki Chiba
  • Publication number: 20040157769
    Abstract: A stabilized pharmaceutical composition in lyophilized form comprising:
    Type: Application
    Filed: February 6, 2004
    Publication date: August 12, 2004
    Applicant: Fujisawa Pharmaceutical Co. Ltd.
    Inventors: Seiji Sawai, Akihiro Kasai, Kazumi Ohtomo
  • Publication number: 20040157891
    Abstract: A compound of the formula (I): 1
    Type: Application
    Filed: January 16, 2004
    Publication date: August 12, 2004
    Applicant: FUJISAWA PHARMACEUTICAL CO., LTD.
    Inventors: Hirofumi Yamamoto, Junya Ishida, Daisuke Tanabe, Shigeki Satoh, Yuki Sawada, Takehiko Ohkawa, Kenichiro Imamura, Katsuya Nakamura
  • Publication number: 20040156855
    Abstract: Agents for promoting fattening of animals which contain as the active ingredient(s) at least one member selected from among acids originating in hexoses, non-toxic salts thereof and intramolecular esterification products thereof; and a method of promoting fattening by using these agents.
    Type: Application
    Filed: February 3, 2004
    Publication date: August 12, 2004
    Applicant: Fujisawa Pharmaceutical Co., Ltd.
    Inventors: Hironari Koyama, Masaaki Okada
  • Patent number: 6774104
    Abstract: A stabilized pharmaceutical composition in lyophilized form comprising: a cyclic polypeptide compound represented by the general formula (I): wherein R1 is a hydrogen atom or an acyl group and R2 and R3 are, the same or different, a hydrogen atom or a hydroxyl group, or a salt thereof and the stabilizer.
    Type: Grant
    Filed: March 1, 2001
    Date of Patent: August 10, 2004
    Assignee: Fujisawa Pharmaceutical Co., Ltd.
    Inventors: Seiji Sawai, Akihiro Kasai, Kazumi Otomo
  • Publication number: 20040152659
    Abstract: Preventives and/or remedies for Parkinson's disease and symptoms associating therewith such as anxiety, depression and/or memory disorder which contain as the active ingredient an adenosine A1A2a receptor dual antagonist or salts thereof.
    Type: Application
    Filed: November 20, 2003
    Publication date: August 5, 2004
    Applicant: Fujisawa Pharmaceutical Co. Ltd.
    Inventors: Nobuya Matsuoka, Akira Moriguchi, Miho Tada, Takuma Mihara
  • Patent number: 6770667
    Abstract: The present invention is a compound and pharmaceutical composition comprising a compound of formula (I): wherein R1 is a 4-(lower) alkyl-imidazol-1-yl or a 4,5-di(lower) alkyl-imidazol-1-yl group, R2 is a hydrogen atom or a lower alkyl group, and R3 is a fluorenyl group. The compound of formula (I) includes pharmaceutically acceptable salts: The compound of formula (I) and salts thereof have 5-HT antagonism activity.
    Type: Grant
    Filed: March 21, 2002
    Date of Patent: August 3, 2004
    Assignee: Fujisawa Pharmaceutical Co., Ltd.
    Inventors: Kiyotaka Ito, Glen W. Spears, Fumie Takahashi, Akira Yamada, Masaki Tomishima, Hiroshi Miyake
  • Patent number: 6765098
    Abstract: A novel means for DNA compaction is provided. The object is accomplished by providing a fullerene derivative having 1 to 4 nitrogen-containing hydrophilic side chain(s) or its salt for DNA compaction. DNA compaction can be achieved effectively, and application to gene therapy is also expected.
    Type: Grant
    Filed: November 17, 2000
    Date of Patent: July 20, 2004
    Assignees: Fujisawa Pharmaceutical Co., Ltd
    Inventors: Eiichi Nakamura, Masaya Sawamura, Hiroyuki Isobe
  • Publication number: 20040132994
    Abstract: The present invention relates to a compound of the formula [I]: 1
    Type: Application
    Filed: October 30, 2003
    Publication date: July 8, 2004
    Applicants: Fujisawa Pharmaceutical Co., Ltd, WAKUNAGA PHARMACEUTICAL CO., LTD.
    Inventors: Hidenori Ohki, Shinya Okuda, Toshio Yamanaka, Masaru Ohgaki, Ayako Toda, Kohji Kawabata, Satoshi Inoue, Keiji Misumi, Kenji Itoh, Kenji Satoh
  • Publication number: 20040133008
    Abstract: A compound of the formula (I) 1
    Type: Application
    Filed: October 28, 2003
    Publication date: July 8, 2004
    Applicants: FUJISAWA PHARMACEUTICAL CO., LTD., DAISO CO., LTD.
    Inventors: Yoshikazu Inoue, Takeshi Terasawa, Hisashi Takasugi, Akira Nagayoshi, Koji Ueshima, Masae Sawada, Yoshiro Furukawa, Masafumi Mikami, Kazumasa Hinoue, Daisuke Fukumoto
  • Publication number: 20040127529
    Abstract: The invention provides an agent for the prevention and/or treatment of skin ulcer or bedsore which comprises a nonprostanoid prostaglandin I2 agonist as an active ingredient.
    Type: Application
    Filed: December 18, 2003
    Publication date: July 1, 2004
    Applicant: Fujisawa Pharmaceutical Co., Ltd.
    Inventors: Masahide Higaki, Emiko Imamura
  • Publication number: 20040116475
    Abstract: A compound of the formula (I): 1
    Type: Application
    Filed: November 14, 2003
    Publication date: June 17, 2004
    Applicant: FUJISAWA PHARMACEUTICAL CO., LTD.
    Inventors: Fumiyuki Shirai, Hidenori Azami, Natsuko Kayakiri, Kazuo Okumura, Katsuya Nakamura
  • Publication number: 20040110264
    Abstract: The present invention is a method for purifying an enzyme, particularly an acylase, comprising causing selective aggregation and precipitation of a contaminant enzyme, particularly deacetylase, by the use of a surfactant, particularly a cationic surfactant. The present invention is also a method for regenerating an immobilized enzyme carrier, particularly a synthetic adsorbent or ion exchange resin, comprising allowing a protease to act on the immobilized enzyme to remove the enzyme from the carrier, said immobilized enzyme being prepared by binding the enzyme with the carrier and optionally crosslinking the enzymes by the use of a crosslinking agent after binding. Particularly, the present invention is the above-mentioned carrier regeneration method, wherein the carrier has fine pores, and the above-mentioned carrier regeneration method, wherein the enzyme is cephalosporin C acylase.
    Type: Application
    Filed: July 30, 2003
    Publication date: June 10, 2004
    Applicant: Fujisawa Pharmaceutical Co. Ltd.
    Inventor: Katsushi Asai
  • Publication number: 20040106653
    Abstract: The present invention relates to a compound formula [I]: 1
    Type: Application
    Filed: November 20, 2003
    Publication date: June 3, 2004
    Applicant: FUJISAWA PHARMACEUTICAL CO., LTD.
    Inventors: Minoru Sakurai, Hitoshi Hamashima, Kouji Hattori
  • Patent number: 6743776
    Abstract: This invention relates to new polypeptide compounds represented by general formula [I]: wherein R1 and R2 are as defined in the description and pharmaceutically acceptable salt thereof which have antimicrobial activities (especially, antifungal activities), inhibitory activity on &bgr;-1,3-glucan synthase, to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for the prophylactic and/or therapeutic treatment of infectious disease including Pneumocystis carinii infection (e.g. Pneumocystis carinii pneumonia) in a human being or an animal.
    Type: Grant
    Filed: May 21, 1999
    Date of Patent: June 1, 2004
    Assignee: Fujisawa Pharmaceutical Co., Ltd.
    Inventors: Hidenori Ohki, Masaki Tomishima, Akira Yamada, Hisashi Takasugi
  • Publication number: 20040087480
    Abstract: Methods and products that modulate the activity of the human epithelial calcium channel type 2 (hECaC2). Modulation of hECaC2 activity permits control of cellular differentiation and proliferation. Such methods and products may be applied to control hyperplastic skin growth in psoriasis and basal and squamous cell carcinomas or to promote tissue repair. Methods for identifying ligands for hECaC2, as well as methods for identifying hECaC2 polypeptides with functional activity.
    Type: Application
    Filed: August 15, 2003
    Publication date: May 6, 2004
    Applicant: Fujisawa Pharmaceutical Co. Ltd.
    Inventors: Stanley G. Rane, Masakazu Kobayashi, Vlasios Manaves, Wuxuan Qin
  • Patent number: 6730776
    Abstract: The present invention provides a new antimicrobial compound WF14573, and a process for producing WF14573 by (a) culturing a WF14573A and/or B-producing microorganism in a nutrient medium and recovering WF14573A and/or B from the resultant cultured broth or (b) deacylating WF14573A and/or B in the presence of a microbial substance which is capable of deacylating WF14573A and/or B. Also provided are an antimicrobial agent comprising WF14573 and carrier(s), a pharmaceutical composition comprising an effective amount of WF14573 and pharmaceutically acceptable carrier(s), a method for killing microorganisms by applying WF14573 to the microorganisms, and use of WF14573 for the treatment of infectious diseases caused by pathogenic microorganisms.
    Type: Grant
    Filed: September 18, 2000
    Date of Patent: May 4, 2004
    Assignee: Fujisawa Pharmaceutical Co., Ltd.
    Inventors: Yasuhiro Hori, Shigehiro Takase, Yasuhisa Tsurumi, Michizane Hashimoto, Motohiro Hino
  • Patent number: 6727245
    Abstract: Heterobicyclic derivatives of the formula: wherein R1 is aryl which may have suitable substituent(s), ar(lower)alkyl which may have suitable substituent(s), halo(lower)alkyl, protected carboxy(lower)alkyl, acyl(lower)alkyl, heterocyclic group or heterocyclic(lower)alkyl which may have suitable substituent(s), R2 is aryl which may have suitable substituent(s) or heterocyclic group, and R3 is hydrogen, lower alkoxy or arylthio, and a pharmaceutically acceptable salt thereof which are useful as a medicament.
    Type: Grant
    Filed: January 18, 2002
    Date of Patent: April 27, 2004
    Assignee: Fujisawa Pharmaceutical Co., Ltd.
    Inventors: Norihiko Shimazaki, Shinya Watanabe, Akihiko Sawada, Keiji Hemmi
  • Patent number: 6718910
    Abstract: Agents for promoting fattening of animals which contain as the active ingredient(s) at least one member selected from among acids originating in hexoses, non-toxic salts thereof and intramolecular esterification products thereof; and a method of promoting fattening by using these agents.
    Type: Grant
    Filed: April 19, 2002
    Date of Patent: April 13, 2004
    Assignee: Fujisawa Pharmaceutical Co., Ltd.
    Inventors: Hironari Koyama, Masaaki Okada